Advertisement

Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus

      Diabetes mellitus (DM) modify outcome in patients with heart failure (HF). We aimed to analyze the risk for death, HF alone, combined end point HF/death, and ventricular tachycardia/ventricular fibrillation (VT/VF) in patients with mild HF without DM and in those with DM, further stratified by the presence of insulin treatment. We determined whether cardiac resynchronization therapy with defibrillator (CRT-D) versus implantable cardioverter defibrillator improves clinical outcomes in these 3 subgroups. Cox proportional hazards regression models were used to analyze 1,278 patients with left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy trial. Treatment with CRT-D versus implantable cardioverter defibrillator was associated with 76% risk reduction in all-cause mortality (hazard ratio 0.24; 95% confidence interval 0.08 to 0.74, p = 0.012) in subgroup of diabetic patients treated with insulin only (interaction p = 0.043). Significant risk reduction in HF alone, HF/death, and the VT/VF after CRT-D was observed across investigated groups and similar left ventricular reverse remodeling to CRT-D. In conclusion, patients with mild HF with DM treated with insulin derive significant risk reduction in mortality, in HF, and VT/VF after implantation of CRT-D. Diabetic patients not receiving insulin benefit from CRT-D by reduction of HF events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • Klein H.
        • Brown M.W.
        • Daubert J.P.
        • Estes III, N.A.
        • Foster E.
        • Greenberg H.
        • Higgins S.L.
        • Pfeffer M.A.
        • Solomon S.D.
        • Wilber D.
        • Zareba W.
        Cardiac-resynchronization therapy for the prevention of heart-failure events.
        N Engl J Med. 2009; 361: 1329-1338
        • Tang A.S.
        • Wells G.A.
        • Talajic M.
        • Arnold M.O.
        • Sheldon R.
        • Connolly S.
        • Hohnloser S.H.
        • Nichol G.
        • Birnie D.H.
        • Sapp J.L.
        • Yee R.
        • Healey J.S.
        • Rouleau J.L.
        Cardiac-resynchronization therapy for mild-to-moderate heart failure.
        N Engl J Med. 2010; 363: 2385-2395
        • Linde C.
        • Abraham W.T.
        • Gold M.R.
        • St John Sutton M.
        • Ghio S.
        • Daubert C.
        Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
        JACC. 2008; 52: 1834-1843
        • Daubert C.
        • Gold M.R.
        • Abraham W.T.
        • Ghio S.
        • Hassager C.
        • Goode G.
        • Szili-Torok T.
        • Linde C.
        Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
        JACC. 2009; 54: 1837-1846
        • Cygankiewicz I.
        • Gillespie J.
        • Zareba W.
        • Brown M.W.
        • Goldenberg I.
        • Klein H.
        • McNitt S.
        • Polonsky S.
        • Andrews M.
        • Dwyer E.M.
        • Hall W.J.
        • Moss A.J.
        Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators.
        Heart Rhythm. 2009; 6: 468-473
        • Alba A.C.
        • Braga J.
        • Gewarges M.
        • Walter S.D.
        • Guyatt G.H.
        • Ross H.J.
        Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.
        Can J Cardiol. 2013; 29: 1729-1740
        • Martin D.T.
        • McNitt S.
        • Nesto R.W.
        • Rutter M.K.
        • Moss A.J.
        Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
        Circ Heart Fail. 2011; 4: 332-338
        • Hoke U.
        • Thijssen J.
        • van Bommel R.J.
        • van Erven L.
        • van der Velde E.T.
        • Holman E.R.
        • Schalij M.J.
        • Bax J.J.
        • Delgado V.
        • Marsan N.A.
        Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy.
        Diabetes Care. 2013; 36: 985-991
        • Masoudi F.A.
        • Inzucchi S.E.
        • Wang Y.
        • Havranek E.P.
        • Foody J.M.
        • Krumholz H.M.
        Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
        Circulation. 2005; 111: 583-590
        • Smooke S.
        • Horwich T.B.
        • Fonarow G.C.
        Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.
        Am Heart J. 2005; 149: 168-174
        • Pocock S.J.
        • Wang D.
        • Pfeffer M.A.
        • Yusuf S.
        • McMurray J.J.
        • Swedberg K.B.
        • Ostergren J.
        • Michelson E.L.
        • Pieper K.S.
        • Granger C.B.
        Predictors of mortality and morbidity in patients with chronic heart failure.
        Eur Heart J. 2006; 27: 65-75
        • Chow E.
        • Bernjak A.
        • Williams S.
        • Fawdry R.A.
        • Hibbert S.
        • Freeman J.
        • Sheridan P.J.
        • Heller S.R.
        Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.
        Diabetes. 2014; 63: 1738-1747
        • Zareba W.
        • Klein H.
        • Cygankiewicz I.
        • Hall W.J.
        • McNitt S.
        • Brown M.
        • Cannom D.
        • Daubert J.P.
        • Eldar M.
        • Gold M.R.
        • Goldberger J.J.
        • Goldenberg I.
        • Lichstein E.
        • Pitschner H.
        • Rashtian M.
        • Solomon S.
        • Viskin S.
        • Wang P.
        • Moss A.J.
        Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT).
        Circulation. 2011; 123: 1061-1072
        • Solomon S.D.
        • Foster E.
        • Bourgoun M.
        • Shah A.
        • Viloria E.
        • Brown M.W.
        • Hall W.J.
        • Pfeffer M.A.
        • Moss A.J.
        Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy.
        Circulation. 2010; 122: 985-992
        • Ghali J.K.
        • Boehmer J.
        • Feldman A.M.
        • Saxon L.A.
        • Demarco T.
        • Carson P.
        • Yong P.
        • Galle E.G.
        • Leigh J.
        • Ecklund F.L.
        • Bristow M.R.
        Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
        J Card Fail. 2007; 13: 769-773
        • Kies P.
        • Bax J.J.
        • Molhoek S.G.
        • Bleeker G.B.
        • Boersma E.
        • Steendijk P.
        • van der Wall E.E.
        • Schalij M.J.
        Comparison of effectiveness of cardiac resynchronization therapy in patients with versus without diabetes mellitus.
        Am J Cardiol. 2005; 96: 108-111
        • Fantoni C.
        • Regoli F.
        • Ghanem A.
        • Raffa S.
        • Klersy C.
        • Sorgente A.
        • Faletra F.
        • Baravelli M.
        • Inglese L.
        • Salerno-Uriarte J.A.
        • Klein H.U.
        • Moccetti T.
        • Auricchio A.
        Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy.
        Eur J Heart Fail. 2008; 10: 298-307
        • Santangelo G.
        • Dugo D.
        • Mule M.
        • Puzzangara E.
        • Schillaci V.
        • Timineri S.
        • Capranzano P.
        • Di Grazia A.
        • Liotta C.
        • Scandura S.
        • Ragusa A.
        • Tamburino C.
        • Calvi V.
        Functional and clinical implications of cardiac resynchronization therapy on outcomes of diabetic patients with heart failure.
        J Cardiovasc Med (Hagerstown). 2011; 12: 396-400
        • Hoppe U.C.
        • Freemantle N.
        • Cleland J.G.
        • Marijianowski M.
        • Erdmann E.
        Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure.
        Diabetes Care. 2007; 30: 722-724
        • Mangiavacchi M.
        • Gasparini M.
        • Genovese S.
        • Pini D.
        • Klersy C.
        • Bragato R.
        • Andreuzzi B.
        • Municino A.
        • Regoli F.
        • Galimberti P.
        • Ceriotti C.
        • Gronda E.
        Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy.
        Pacing Clin Electrophysiol. 2008; 31: 1425-1432
        • Shah R.V.
        • Altman R.K.
        • Park M.Y.
        • Zilinski J.
        • Leyton-Mange J.
        • Orencole M.
        • Picard M.H.
        • Barrett C.D.
        • Heist E.K.
        • Upadhyay G.
        • Das R.
        • Singh J.P.
        • Das S.
        Usefulness of hemoglobin A(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failure.
        Am J Cardiol. 2012; 110: 683-688
        • Chaudhuri A.
        • Janicke D.
        • Wilson M.F.
        • Tripathy D.
        • Garg R.
        • Bandyopadhyay A.
        • Calieri J.
        • Hoffmeyer D.
        • Syed T.
        • Ghanim H.
        • Aljada A.
        • Dandona P.
        Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction.
        Circulation. 2004; 109: 849-854
        • Lautamaki R.
        • Airaksinen K.E.
        • Seppanen M.
        • Toikka J.
        • Harkonen R.
        • Luotolahti M.
        • Borra R.
        • Sundell J.
        • Knuuti J.
        • Nuutila P.
        Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease.
        Diabetes. 2006; 55: 511-516
        • DeFronzo R.A.
        • Cooke C.R.
        • Andres R.
        • Faloona G.R.
        • Davis P.J.
        The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.
        J Clin Invest. 1975; 55: 845-855
        • Kirk J.A.
        • Holewinski R.J.
        • Kooij V.
        • Agnetti G.
        • Tunin R.S.
        • Witayavanitkul N.
        • de Tombe P.P.
        • Gao W.D.
        • Van Eyk J.
        • Kass D.A.
        Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3beta.
        J Clin Invest. 2014; 124: 129-138
        • Colayco D.C.
        • Niu F.
        • McCombs J.S.
        • Cheetham T.C.
        A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study.
        Diabetes Care. 2011; 34: 77-83
        • Margolis D.J.
        • Hoffstad O.
        • Strom B.L.
        Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
        Pharmacoepidemiol Drug Saf. 2008; 17: 753-759
        • Nordin C.
        The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia.
        Acta Diabetol. 2014; 51: 5-14
        • Zoungas S.
        • Patel A.
        • Chalmers J.
        • de Galan B.E.
        • Li Q.
        • Billot L.
        • Woodward M.
        • Ninomiya T.
        • Neal B.
        • MacMahon S.
        • Grobbee D.E.
        • Kengne A.P.
        • Marre M.
        • Heller S.
        • Group A.C.
        Severe hypoglycemia and risks of vascular events and death.
        N Engl J Med. 2010; 363: 1410-1418
        • Bertoni A.G.
        • Krop J.S.
        • Anderson G.F.
        • Brancati F.L.
        Diabetes-related morbidity and mortality in a national sample of U.S. elders.
        Diabetes Care. 2002; 25: 471-475